MoonLake Immunotherapeutics (MLTX) is a high-conviction buy based on its proprietary nanobody technology, strong institutional ownership, and upcoming catalysts like Phase 3 data and a pre-BLA meeting, with analysts setting a $70 price target.
Source Post
MoonLake MLTX Soars: $70 Target After Upgrades! | MLTX Stock Analysis
Apr 15, 2026
The podcast discusses MoonLake Immunotherapeutics (MLTX), a pre-revenue clinical-stage biopharmaceutical company focused on nanobody technology for treating hidradenitis suppurativa. Despite high cash burn, significant institutional ownership and recent analyst upgrades to a $70 price target suggest strong conviction in its lead drug candidate, sonelokimab. Key upcoming catalysts include Phase 3 data and a pre-BLA meeting with the FDA. Risks include intense competition and potential commercial execution challenges, with Goldman Sachs maintaining a sell rating.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
MLTXbuy opened Apr 15, 2026
+5.86%